Találati lista | Tudóstér

001-es BibID:	BIBFORM005643
Első szerző:	Yusuf, Salim (belgyógyász)
Cím:	Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors : a randomised controlled trial / Yusuf, S., Teo, K. K., Anderson, C., Pogue, J., Dyal, L., Copland, I., Schumacher, H., Dagenais, G., Sleight, P., Ferrari, R., Ford, I., Fox, K., Steg, P. G., Tendera, M., TRANSCEND Investigators
Dátum:	2008
ISSN:	1474-547X (Electronic)
Megjegyzések:	Angiotensin-converting enzyme (ACE) inhibitors reduce major cardiovascular events, but are not tolerated by about 20% of patients. We therefore assessed whether the angiotensin-receptor blocker telmisartan would be effective in patients intolerant to ACE inhibitors with cardiovascular disease or diabetes with end-organ damage. METHODS: After a 3-week run-in period, 5926 patients, many of whom were receiving concomitant proven therapies, were randomised to receive telmisartan 80 mg/day (n=2954) or placebo (n=2972) by use of a central automated randomisation system. Randomisation was stratified by hospital. The primary outcome was the composite of cardiovascular death, myocardial infarction, stroke, or hospitalisation for heart failure. Analyses were done by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00153101. FINDINGS: The median duration of follow-up was 56 (IQR 51-64) months. All randomised patients were included in the efficacy analyses. Mean blood pressure was lower in the telmisartan group than in the placebo group throughout the study (weighted mean difference between groups 4.0/2.2 [SD 19.6/12.0] mm Hg). 465 (15.7%) patients experienced the primary outcome in the telmisartan group compared with 504 (17.0%) in the placebo group (hazard ratio 0.92, 95% CI 0.81-1.05, p=0.216). One of the secondary outcomes-a composite of cardiovascular death, myocardial infarction, or stroke-occurred in 384 (13.0%) patients on telmisartan compared with 440 (14.8%) on placebo (0.87, 0.76-1.00, p=0.048 unadjusted; p=0.068 after adjustment for multiplicity of comparisons and overlap with primary outcome). 894 (30.3%) patients receiving telmisartan were hospitalised for a cardiovascular reason, compared with 980 (33.0%) on placebo (relative risk 0.92, 95% CI 0.85-0.99; p=0.025). Fewer patients permanently discontinued study medication in the telmisartan group than in the placebo group (639 [21.6%] vs 705 [23.8%]; p=0.055); the most common reason for permanent discontinuation was hypotensive symptoms (29 [0.98%] in the telmisartan group vs 16 [0.54%] in the placebo group). INTERPRETATION: Telmisartan was well tolerated in patients unable to tolerate ACE inhibitors. Although the drug had no significant effect on the primary outcome of this study, which included hospitalisations for heart failure, it modestly reduced the risk of the composite outcome of cardiovascular death, myocardial infarction, or stroke.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban Aged Angioedema/chemically induced Angiotensin-Converting Enzyme Inhibitors/adverse effects/ therapeutic use Benzimidazoles/adverse effects/ therapeutic use Benzoates/adverse effects/ therapeutic use Cardiovascular Diseases/ prevention and control Cough/chemically induced Female Follow-Up Studies Humans Hypotension/chemically induced Kaplan-Meiers Estimate Male Risk Reduction Behavior Single-Blind Method Therapeutic Equivalency Benzazepines/ therapeutic use Cardiovascular Agents/ therapeutic use Coronary Artery Disease/complications/ drug therapy/mortality Diabetes Complications Double-Blind Method Drug Therapy, Combination Heart Failure/ drug therapy/etiology Metabolic Syndrome X/complications Middle Aged Myocardial Infarction/complications Ventricular Dysfunction, Left/drug therapy/etiology Angiotensin II Type 1 Receptor Blockers/adverse effects/ therapeutic use Blood Pressure/drug effects Cardiovascular Diseases/ drug therapy/epidemiology/mortality Creatinine/blood Diabetes Mellitus/ drug therapy Hospitalization Ramipril/adverse effects/ therapeutic use Risk
Megjelenés:	Lancet. - 372 : 9644 (2008), p. 1174-1183. -
További szerzők:	Teo, K. K. Anderson, C. Pogue, J. Dyal, L. Copland, I. Schumacher, H. Dagenais, G. Sleight, Peter Ferrari, Roberto Ford, Ian Fox, K. Steg, Philippe Gabriel Tendera, Michal Édes István (1952-) (kardiológus) Czuriga István (1948-2018) (kardiológus) TRANSCEND Investigators
Internet cím:	DOI elektronikus változat
Borító:
Saját polcon: